SOPHiA GENETICS and Jessa Ziekenhuis Announce Partnership in Precision Oncology at European Congress of Pathology
SOPHiA GENETICS, a leading cloud-native healthcare technology company, has announced a significant partnership with Jessa Ziekenhuis in Hasselt, Belgium. The collaboration aims to provide advanced genomic testing and oncological research for cancer patients across Belgium. By leveraging SOPHiA GENETICS' automated, cloud-native solutions tailored for oncology, Jessa Ziekenhuis will be able to streamline workflows, accelerate insights, and enhance patient care throughout the country. This partnership marks an expansion of SOPHiA GENETICS' presence in European hospital networks, furthering the advancement of data-driven precision medicine.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief via PR Newswire (Ref. ID: GE65965) on September 08, 2025, and is solely responsible for the information contained therein.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。